ReviewPituitary2017
Biochemical investigations in diagnosis and follow up of acromegaly.
Review in Pituitary, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Prevalence and patterns of biochemical discordance in patients with surgically treated acromegaly.Pituitary · 2026Article
- Review
- Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly.Journal of endocrinological investigation · 2024Article
- Intraocular Pressure (IOP) in Patients with Acromegaly versus Healthy Controls: A Systematic Review and Meta-Analysis.Vision (Basel, Switzerland) · 2024Review
- Pitfalls in the lab assessment of hypopituitarism.Reviews in endocrine & metabolic disorders · 2024Review
- Delving into Acromegaly.Journal of clinical medicine · 2023Article
- Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly.Frontiers in endocrinology · 2023Review
- Sex difference in patients with controlled acromegaly-A multicentre survey.Clinical endocrinology · 2023Article
- Acromegaly: Clinical Care in Central and Eastern Europe, Israel, and Kazakhstan.Frontiers in endocrinology · 2022Review
- Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity.The Journal of clinical endocrinology and metabolism · 2021Article
- The Biochemical Diagnosis of Acromegaly.Journal of clinical medicine · 2021Review
- Multidisciplinary management of acromegaly: A consensus.Reviews in endocrine & metabolic disorders · 2020Review
- Model informed quantification of the feed-forward stimulation of growth hormone by growth hormone-releasing hormone.British journal of clinical pharmacology · 2020Article
- Acromegaly with congenital generalized lipodystrophy - two rare insulin resistance conditions in one patient: a case report.Journal of medical case reports · 2020Article
- Octreotide-Resistant Acromegaly: Challenges and Solutions.Therapeutics and clinical risk management · 2020Review
- Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues.Endocrine, metabolic & immune disorders drug targets · 2020Review
- Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.Reviews in endocrine & metabolic disorders · 2019Review
- A Consensus Statement on acromegaly therapeutic outcomes.Nature reviews. Endocrinology · 2018Review
- Review
- Silent somatotroph pituitary adenomas: an update.Pituitary · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Measurements of human growth hormone (GH) and insulin-like growth-factor I (IGF-I) are cornerstones in the diagnosis of acromegaly. Both hormones are also used as biochemical markers in the evaluation of disease activity during treatment. Management of acromegaly is particularly challenging in cases where discordant information is obtained from measurement of GH concentrations following oral glucose load and from measurement of IGF-I. While in some patients biological factors can explain the discrepancy, in many cases issues with the analytical methods seem to be responsible. Assays used by endocrine laboratories to determine concentrations of GH and IGF-I underwent significant changes during the last decades. While generally leading to more sensitive and reproducible methods, these changes also had considerable impact on absolute concentrations measured. This must be reflected by updated decision limits, cut-offs and reference intervals. Since different commercially available assays do not agree very well, method specific interpretation of GH and IGF-I concentrations is required. This complexity in the interpretation of hormone concentrations is not always appropriately reflected in laboratory reports, but also not in clinical guidelines reporting decision limits not related to a specific analytical method. The present review provides an overview about methodological and biological variables affecting the biochemical assessment of acromegaly in diagnosis and follow up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.